JP2023507402A - Ｃ１７位に窒素ベースの置換基を有する合成トリテルペノイドおよびその使用方法 - Google Patents

Ｃ１７位に窒素ベースの置換基を有する合成トリテルペノイドおよびその使用方法 Download PDF

Info

Publication number
JP2023507402A
JP2023507402A JP2022537305A JP2022537305A JP2023507402A JP 2023507402 A JP2023507402 A JP 2023507402A JP 2022537305 A JP2022537305 A JP 2022537305A JP 2022537305 A JP2022537305 A JP 2022537305A JP 2023507402 A JP2023507402 A JP 2023507402A
Authority
JP
Japan
Prior art keywords
compound
alkyl
substituted
hydrogen
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507402A5 (https=
Inventor
クリストファー エフ． ベンダー
ハ ド
シン ジアン
ハイチョウ スン
メレアン ビスニック
インゴ ヤンサー
ロイド ジェイ． シモンズ
ハインリヒ ジェイ． ショスタレス
Original Assignee
リアタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リアタ ファーマシューティカルズ インコーポレイテッド filed Critical リアタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2023507402A publication Critical patent/JP2023507402A/ja
Publication of JP2023507402A5 publication Critical patent/JP2023507402A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022537305A 2019-12-19 2020-12-18 Ｃ１７位に窒素ベースの置換基を有する合成トリテルペノイドおよびその使用方法 Pending JP2023507402A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962950927P 2019-12-19 2019-12-19
US201962950919P 2019-12-19 2019-12-19
US62/950,919 2019-12-19
US62/950,927 2019-12-19
US202063198310P 2020-10-09 2020-10-09
US63/198,310 2020-10-09
PCT/US2020/066073 WO2021127480A1 (en) 2019-12-19 2020-12-18 Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023507402A true JP2023507402A (ja) 2023-02-22
JP2023507402A5 JP2023507402A5 (https=) 2023-12-25

Family

ID=74554207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537305A Pending JP2023507402A (ja) 2019-12-19 2020-12-18 Ｃ１７位に窒素ベースの置換基を有する合成トリテルペノイドおよびその使用方法

Country Status (20)

Country Link
US (1) US20230111914A1 (https=)
EP (1) EP4077347A1 (https=)
JP (1) JP2023507402A (https=)
KR (1) KR20220116209A (https=)
CN (1) CN115087660A (https=)
AU (1) AU2020405181A1 (https=)
BR (1) BR112022011919A2 (https=)
CA (1) CA3159778A1 (https=)
CL (1) CL2022001661A1 (https=)
CO (1) CO2022010070A2 (https=)
CR (1) CR20220345A (https=)
DO (1) DOP2022000127A (https=)
EC (1) ECSP22055210A (https=)
IL (1) IL293876B2 (https=)
MX (1) MX2022007595A (https=)
PE (1) PE20221662A1 (https=)
PH (1) PH12022551493A1 (https=)
SA (1) SA522432999B1 (https=)
TW (1) TWI889738B (https=)
WO (1) WO2021127480A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
AU2021397631A1 (en) * 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129548A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
WO2009129546A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US20110245233A1 (en) * 2008-04-18 2011-10-06 Eric Anderson Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096046A1 (es) * 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
MX2021003643A (es) * 2018-09-28 2021-08-19 Sichuan Haisco Pharmaceutical Co Ltd Derivados de terpenoides y usos de los mismos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129548A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
WO2009129546A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US20110245233A1 (en) * 2008-04-18 2011-10-06 Eric Anderson Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring

Also Published As

Publication number Publication date
IL293876B2 (en) 2026-03-01
US20230111914A1 (en) 2023-04-13
CO2022010070A2 (es) 2022-08-09
PH12022551493A1 (en) 2023-11-13
IL293876A (en) 2022-08-01
IL293876B1 (en) 2025-11-01
TW202135828A (zh) 2021-10-01
MX2022007595A (es) 2022-07-19
SA522432999B1 (ar) 2025-04-10
CA3159778A1 (en) 2021-06-24
BR112022011919A2 (pt) 2022-09-06
CN115087660A (zh) 2022-09-20
PE20221662A1 (es) 2022-10-26
KR20220116209A (ko) 2022-08-22
DOP2022000127A (es) 2022-09-15
CL2022001661A1 (es) 2023-01-27
ECSP22055210A (es) 2022-08-31
AU2020405181A1 (en) 2022-07-14
EP4077347A1 (en) 2022-10-26
WO2021127480A1 (en) 2021-06-24
CR20220345A (es) 2023-01-12
TWI889738B (zh) 2025-07-11

Similar Documents

Publication Publication Date Title
JP2023507402A (ja) Ｃ１７位に窒素ベースの置換基を有する合成トリテルペノイドおよびその使用方法
KR102891865B1 (ko) C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
AU2011343466A1 (en) Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
CA2974726C (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators
JP2024504637A (ja) 合成ウルソール酸誘導体及びその使用方法
EA049347B1 (ru) Синтетические тритерпеноиды с заместителями на основе азота у атома c-17 и способы их применения
HK40080975A (en) Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof
HK40073498B (zh) C17极性的-取代的杂芳族合成三萜类化合物及其使用方法
HK40073498A (en) C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
HK1212355B (zh) 齐墩果酸的c17-烷二基与烯二基衍生物及其使用方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250904